Neogenomics (NEO) Income towards Parent Company (2016 - 2026)
Neogenomics filings provide 17 years of Income towards Parent Company readings, the most recent being -$17.1 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company rose 34.01% to -$17.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$99.2 million, a 27.87% decrease, with the full-year FY2025 number at -$108.0 million, down 37.22% from a year prior.
- Income towards Parent Company hit -$17.1 million in Q1 2026 for Neogenomics, down from -$9.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$9.9 million in Q4 2025 to a low of -$49.4 million in Q1 2022.
- Median Income towards Parent Company over the past 5 years was -$24.3 million (2023), compared with a mean of -$25.7 million.
- Biggest five-year swings in Income towards Parent Company: tumbled 146.53% in 2022 and later surged 49.76% in 2023.
- Neogenomics' Income towards Parent Company stood at -$22.7 million in 2022, then soared by 36.85% to -$14.3 million in 2023, then dropped by 6.97% to -$15.3 million in 2024, then surged by 35.52% to -$9.9 million in 2025, then crashed by 73.12% to -$17.1 million in 2026.
- The last three reported values for Income towards Parent Company were -$17.1 million (Q1 2026), -$9.9 million (Q4 2025), and -$27.1 million (Q3 2025) per Business Quant data.